400,000 Shares in Drugs Made In America Acquisition II Corp. $DMII Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 400,000 shares of the company’s stock, valued at approximately $3,960,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC purchased a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $265,000. ABC Arbitrage SA purchased a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $396,000. Deltec Asset Management LLC purchased a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $495,000. Wealthspring Capital LLC purchased a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $4,049,000. Finally, HighTower Advisors LLC purchased a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $7,817,000.

Drugs Made In America Acquisition II Stock Up 0.0%

Drugs Made In America Acquisition II stock opened at $10.08 on Thursday. Drugs Made In America Acquisition II Corp. has a twelve month low of $9.86 and a twelve month high of $10.07. The stock’s 50 day moving average is $10.02.

Wall Street Analysts Forecast Growth

DMII has been the topic of a number of research reports. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings restated a “sell (e)” rating on shares of Drugs Made In America Acquisition II in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.